UPPER GASTROINTESTINAL SAFETY WITH THE BUFFERED SOLUTION OF ALENDRONATE 70 MG: POST-MARKETING EXPERIENCE

被引：0
|
作者：
Hruska, J. [1 ]
Jorgensen, F. K. [2 ]
Pierleoni-Nielsen, C. [2 ]
Eriksen, E. F. [3 ]
机构：
[1] McDACom GmbH, Zurich, Switzerland
[2] Klifo AS, Glostrup, Denmark
[3] Oslo Univ Hosp, Dept Clin Endocrinol, Oslo, Norway
来源：
OSTEOPOROSIS INTERNATIONAL | 2017年 / 28卷
关键词：
OSTEOPOROSIS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P589
引用
收藏
页码：S366 / S366
页数：1
相关论文
共 50 条
  • [21] Post-marketing device safety surveillance
    Vidi, Venkatesan D.
    Matheny, Michael E.
    Resnic, Frederic S.
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 (03) : 307 - 308
  • [22] Upper gastrointestinal tolerability of once-weekly alendronate 70 mg with concomitant NSAID use
    de Papp, AE
    Palmisano, J
    Thompson, D
    Geba, GP
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S42 - S43
  • [23] Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant NSAID use.
    de Papp, AE
    Palmisano, J
    Petruschke, RA
    Geba, GP
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (04) : S106 - S106
  • [24] Upper gastrointestinal tolerability of once-weekly alendronate 70 mg with concomitant NSAID use
    De Papp, A
    Palmisano, J
    Petruschke, R
    Geba, G
    GASTROENTEROLOGY, 2003, 124 (04) : A168 - A168
  • [25] Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
    Travis, S.
    Ungaro, R.
    Blake, A.
    Bhayat, F.
    Card, T.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S337 - S338
  • [26] Renal safety and tolerability of ibandronate in clinical practice:: Post-marketing experience in Germany
    Seraphin, Joerg
    Schuetz, Florian
    Nusch, Arnd
    Meden, Harald
    ANNALS OF ONCOLOGY, 2006, 17 : 290 - 291
  • [27] POST-MARKETING SAFETY EXPERIENCE OF VEDOLIZUMAB IN OLDER PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Travis, Simon P.
    Ungaro, Ryan C.
    Blake, Aimee
    Bhayat, Fatima
    Card, Timothy
    GASTROENTEROLOGY, 2018, 154 (06) : S362 - S362
  • [28] SAFETY OF ESLICARBAZEPINE ACETATE AFTER 4 YEARS OF POST-MARKETING EXPERIENCE IN EUROPE
    Gama, H.
    Vieira, M.
    Costa, R.
    Sousa, R.
    Pinto, R.
    Soares-da-Silva, P.
    EPILEPSIA, 2014, 55 : 113 - 113
  • [29] Ibrutinib: A post-marketing safety analysis.
    Elias, Rawad
    Pudusseri, Anita
    Akinboro, Oladimeji
    White, Paul S.
    Sarosiek, Shayna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Post-marketing safety profile of pethidine in Indonesia
    Haposan, Jonathan Hasian
    Thobari, Jarir At
    Nurwahidin, Muhammad
    Chandra, Lukman Ade
    Hidayati, Nastia
    Dewi, Rianiasa Karunia
    Pudjiati, Dyah Juliana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 226 - 227
12345